After H.C. Wainwright and Maxim Group gave Coherus Biosciences (NASDAQ: CHRS) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Salim Syed maintained a Buy rating on Coherus Biosciences today and set a price target of $43.00. The company’s shares closed last Monday at $17.74.
According to TipRanks.com, Syed is a 1-star analyst with an average return of -2.4% and a 51.6% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Unity Biotechnology.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coherus Biosciences with a $33.75 average price target, a 77.0% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $29.00 price target.
Based on Coherus Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $47.04 million. In comparison, last year the company had a GAAP net loss of $58.81 million.
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar.